Toggle Main Menu Toggle Search

Open Access padlockePrints

Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ(10))

Lookup NU author(s): Professor Rita Horvath

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Riboflavin and ubiquinone (Coenzyme Q(10), CoQ(10)) deficiencies are heterogeneous groups of autosomal recessive conditions affecting both children and adults. Riboflavin (vitamin B-2)-derived cofactors are essential for the function of numerous dehydrogenases. Genetic defects of the riboflavin transport have been detected in Brown-Vialetto-Van Laere and Fazio-Londe syndromes (C20orf54), and haploinsufficiency of GPR172B has been proposed in one patient to cause persistent riboflavin deficiency. Mutations in the electron tranferring fravoprotein genes (ETFA/ETFB) and its dehydrogenase (ETFDH) are causative for multiple acyl-CoA dehydrogenase deficiency. Mutations in ACAD9, encoding the acyl-CoA dehydrogenase 9 protein were recently reported in mitochondrial disease with respiratory chain complex I deficiency. All these conditions may respond to riboflavin therapy. CoQ(10) is a lipid-soluble component of the cell membranes, where it functions as a mobile electron and proton carrier, but also participates in other cellular processes as a potent antioxidant, and by influencing pyrimidine metabolism. The increasing number of molecular defects in enzymes of the CoQ(10) biosynthetic pathways (PDSS1, PDSS2, COQ2, COQ6, COQ9, CABC1/ADCK3) underlies the importance of these conditions. The clinical heterogeneity may reflect blocks at different levels in the complex biosynthetic pathway. Despite the identification of several primary CoQ(10) deficiency genes, the number of reported patients is still low, and no true genotype-phenotype correlations are known which makes the genetic diagnosis still difficult. Additionally to primary CoQ(10) deficiencies, where the mutation impairs a protein directly involved in CoQ(10) biosynthesis, we can differentiate secondary deficiencies. CoQ(10) supplementation may be beneficial in both primary and secondary deficiencies and therefore the early recognition of these diseases is of utmost importance.


Publication metadata

Author(s): Horvath R

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: Annual Symposium of the Society for Study of Inborn Errors of Metabolism (SSIEM)

Year of Conference: 2012

Pages: 679-687

ISSN: 0141-8955

Publisher: Springer

URL: http://dx.doi.org/10.1007/s10545-011-9434-1

DOI: 10.1007/s10545-011-9434-1

Library holdings: Search Newcastle University Library for this item

Series Title: Journal of Inherited Metabolic Disease

ISBN: 15732665


Actions

Find at Newcastle University icon    Link to this publication


Share